Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Cancer. 2019 May 8;125(17):3013–3024. doi: 10.1002/cncr.32162

Figure 1.

Figure 1.

Kaplan Meier Estimates of Recurrence Free Survival (RFS) for Patients Treated on A) E1684: HR = 0.73 [95% CI: 0.56, 0.97], B) E1690: HR=0.82 [95% CI: 0.64, 1.05], C) E1694: HR=0.82 [95% CI: 0.69, 0.99] and D) E2696: Concurrent vs. GMK alone HR = 0.75 [95% CI: 0.42, 1.34], sequential vs. GMK alone HR = 0.61 [95% CI:0.33, 1.12].